Buy Rating Affirmed: Taysha Gene Therapies Poised for Breakthrough on Pediatric Data and FDA Support

In a report released yesterday, Jack Allen from Robert W. Baird maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price target of $7.00.

Jack Allen has given his Buy rating due to a combination of factors surrounding Taysha Gene Therapies’ promising developments and regulatory advancements. The company’s clinical-stage gene therapy pipeline, particularly TSHA-102, is approaching significant milestones with the upcoming release of pediatric data at the IRSF meeting. This event is anticipated to be a crucial catalyst, as it will be the first time pediatric trial data is disclosed, offering insights into the therapy’s efficacy in younger patients with Rett Syndrome. Allen’s optimism is further supported by the diverse metrics used in the trial, which aim to provide a comprehensive view of the early effects of the treatment in both severe and mild genotypes of the condition.
Additionally, Taysha’s recent RMAT designation from the FDA for TSHA-102 underscores the therapy’s potential and could facilitate a more efficient development process. The designation also reflects the FDA’s supportive stance on gene therapy innovation, which could act as a favorable industry tailwind. Furthermore, the company’s financial position, with $124 million in cash reserves as of 1Q24, is expected to fund operations well into 2026, reducing immediate financial risk. This combination of upcoming data releases, regulatory support, and financial stability forms the basis for Allen’s Buy rating on Taysha Gene Therapies.

In another report released today, JMP Securities also maintained a Buy rating on the stock with a $5.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Taysha Gene Therapies (TSHA) Company Description:

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.